Published: 2019-10-22 10:16:09 CEST
Grindeks
Inside information

JSC “Grindeks” oxytocin inclusion in World Health Organization List of Prequalified Medicinal Products provides new opportunities in international tenders

JSC “Grindeks” informs that World Health Organization (WHO) has included oxytocin solution for injection 10 IU/ml in the List of Prequalified Medicinal Products.

“Grindeks” oxytocin in the List of Prequalified Medicinal Products was included after 2 years of purposeful work and inspections of manufacturing sites. For the final dosage form (FDF) oxytocin to be prequalified, “Grindeks” had to receive WHO conclusions that the FDF meets several eligibility criteria. Company had to prepare product dossier with detailed information attesting to the quality, safety and efficacy of the product, and also had to demonstrate that the FDF is stable under climatic conditions prevailing in the country or countries in which the FDF is intended to be used. The stability-testing program and conditions had to correspond with WHO quality guidelines. All necessary tests were carried out for both the active pharmaceutical ingredient (API) the medicine contains and the FDF. Mandatory prequalification related tests were carried out at the sites where the FDF is manufactured – “Grindeks” Group’s company “HBM Pharma” in Slovakia and “Satonika” in Lithuania. The API oxytocin is manufactured in Latvia.

JSC “Grindeks” Chairman of the Board Juris Bundulis: “Oxytocin inclusion in WHO medicine list gives us new opportunities in WHO organized international tenders for medicines and has once more acknowledged “Grindeks” ability to be competitive in global scale. We will be able to offer oxytocin in new markets, and that will enhance “Grindeks” recognition and representation in the international pharmaceutical market. This is an important milestone – an evidence of the high quality of our products and our team professionalism. “Grindeks” is constantly developing.”

WHO prequalification of FDF provides assurance that the FDF meets international standards of quality, safety and efficacy and WHO Good Manufacturing Practice. In total 76 manufacturers from 29 countries has an FDF or FDFs listed on the WHO List of Prequalified Medicinal Products and 46 manufacturers from 6 countries has an API or APIs listed on the WHO List of Prequalified Active Pharmaceutical Ingredients.

“Grindeks” sales volume of the FDF oxytocin and API oxytocin in 2018 reached 4.5 million euro.

Oxytocin is a medicine used in medical institutions in obstetrics.


About JSC “Grindeks”

“Grindeks” is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” has four subsidiary companies in Latvia, Estonia, and Slovakia as well as representative offices in 11 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics, food supplements and active pharmaceutical ingredients.

In 2018, products of the company were exported to 87 countries with export comprising 93% of the total turnover. The most significant “Grindeks” markets include the EU countries, Russia and the other CIS countries, the U.S., Canada, Japan and Vietnam.

To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing nearly 105 million euros over the last 15 years.

*Notice: meldonium is included in the list of substances prohibited in sport.


Further information:

Olga Grisina, Public Relations Specialist, JSC “Grindeks”

Phones: (+371) 67083334

Email: olga.grisina@grindeks.lv

www.grindeks.eu